Dr. Frances Shepherd CV - (NCRI) is

Association of Radiation Oncology (CARO) Annual Meeting, Vancouver. Radiother
Oncol 96(Supp 2): S59, A182, 2010.
49. Giuliani ME, Lindsay PE, Sun A, Bezjak A, Le LW, Brade A, Cho J, Leighl N,
Shepherd FA, Hope AJ. Patterns of failure in patients with limited-stage small cell lung
carcinoma. American Society of Radiation Oncology (ASTRO) Annual Meeting, San
Diego. Int J Radiat Oncol Biol Phys 78(Supp 3): S495, A2652, 2010.
50. Hope AJ, Coate LE, Massey C, Sacher A, Barrett K, Keshavjee S, Darling G, Leighl NB,
Bezjak A, Shepherd FA. Outcomes of bimodality and trimodality therapy in patients
with stage III non-small cell lung cancer (NSCLC). American Society of Radiation
Oncology (ASTRO) Annual Meeting, San Diego. Int J Radiat Oncol Biol Phys 78(Supp
3): S505, A2673, 2010.
51. Giuliani M, Lindsay PE, Brade AM, Sun A, Bezjak A, Shepherd FA, Hope A. Outcomes
of salvage therapy in patients with limited stage small cell lung cancer with isolated locoregional
failure. J Thorac Oncol 2010; 5: S550.
52. Ellis PM, Zhang J, Jones M, Jungnelius J, Shepherd FA. Phase I study of
pomalidomide
53. in combination with cisplatin and etoposide in extensive stage small cell lung cancer with
54. isolated loco-regional failure. J Thorac Oncol 2010; 5: S551.
55. Cuffe S. Ezzalfani M, Graziano S, Pignon JP, Seymour L, Strevel E, Burkes R,
Shepherd FA. A pooled exploratory analysis of the effect of tumour size on survival
benefit from platinum-based adjuvant chemotherapy in node negative non-small cell lung
cancer. J Thorac Oncol 2010; 5: S551.
56. Gauthier LR, Robert H. Dworkin, Ronald Melzack, G. Rodin, C. Zimmermann, D. Warr,
S.L. Librach, M. Moore, Shepherd FA, L. Gagliese. Age and gender-related patterns in
cancer pain severity and qualities. Presented at the Canadian Pain Society Conference,
April, 2010
57. Goss GD, Lorimer I, Tsao MS, O’Callaghan CJ, Ding K, Masters GA, Roberts P, Jett JR,
Edelman MJ, Shepherd FA. A phase III randomized, double-blind, placebo-controlled
trial of epidermal growth factor receptor inhibitor gefitinib in completely resected stage
IB-IIIA non-small cell lung cancer (NSCLC): NCIC BR.19. Presented at ASCO,
Chicago, IL June 2010.
58. John T, Kohler D, Yanagawa, N, Pintille M, Li M, Panchal D, Pham N, Der S, Shepherd
FA, Tsao MS. Correlation of engraftment, mutation status, and response to chemotherapy
in primary tumor xenograft models of NSCLC. Presented at ASCO, Chicago, IL June
2010.
59. Bezjak A, Leighl NB, GDarling GE, Sun A, Keshavjee S, Shepherd FA. Treatment of the
elderly when cure is the goal: the influence of age on treatment selection and efficacy for
stage III non-small cell lung cancer (NSCLC). Presented at ASCO, Chicago, IL June
2010.
60. Booth CM, Shepherd FA, Peng Y, Darling GE, Li G, Kong W, Mackillop WJ. Adoption
of adjuvant chemotherapy for non-small cell lung cancer: A population-based outcomes
study. Presented at ASCO, Chicago, IL June 2010.
61. Brade Am, Bezjak A, MacRae RM, Laurie SA, Wang L, Capobianco S, Shepherd FA. A
phase II study of concurrent pemetrexed/cisplatin/radiation (RT) for unresectable stage
IIIA/b non-small cell lung cancer (NSCLC). Presented at ASCO, Chicago, IL June 2010.
62. Liu G, Cheng D, LeMaitre A, Liu N, Chen Z, Seymour L, Ding K, Shepherd FA, Tsao
MS. EGFR and ABCG2 polymorphisms as prognostic and predictive markers in the
NCIC CTG BR.21 trial of single-agent erlotinib and advanced non-small cell lung cancer
(NSCLC). Presented at ASCO, Chicago, IL June 2010
63. Coate LE, Massey C, Hope AJ, Pierre A, Bezjak A, Leighl NB, Darling GE, Sun A,
Keshavjee S, Shepherd FA. Treatment of the elderly when cure is the goal: the influence
21